Lancet Respir Med

Triple therapy boosts lung function in uncontrolled asthma

March 20, 2026

In the twin phase 3 KALOS and LOGOS trials, single‑inhaler triple therapy with budesonide–glycopyrronium–formoterol (BGF) improved lung function and reduced severe exacerbations in adolescents and adults with asthma inadequately controlled on medium‑ or high‑dose ICS–LABA. In pooled analyses of more than 4,300 treated patients, BGF improved morning pre‑dose trough FEV₁ by ~76 mL and FEV₁ FEV₁ AUC_0-3 by ~90 mL over 24 weeks versus dual ICS–LABA therapy (both p<0.001). BGF also lowered the annualized rate of severe asthma exacerbations compared with ICS–LABA comparators, including in patients without a recent exacerbation history. Adverse event rates were similar across treatment groups, with no new safety signals identified.

Clinical takeaway: For patients aged ≥12 years with persistent symptoms or exacerbations despite medium- or high-dose ICS–LABA, consider stepping up to single-inhaler triple therapy with ICS/LABA/LAMA to improve lung function and reduce severe exacerbation risk.

Source:

Papi A, et al; KALOS and LOGOG study investigators. (2026, February 28). Lancet Respir Med. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. https://pubmed.ncbi.nlm.nih.gov/41692019/